A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and efficacy of up to three
concentrations of DE-117 ophthalmic solution (Low Dose, Medium Dose, and High Dose) as
monotherapy and as adjunctive therapy (DE-117 ophthalmic solution with 0.0015% tafluprost) in
subjects with primary open-angle glaucoma or ocular hypertension.